127 results
Page 5 of 7
8-K
6c9rn07k7 xw
14 Aug 20
Equillium Announces Proposed Public Offering of Common Stock
4:50pm
8-K
EX-99.1
43qtvcg67fvsrjan6u
14 Aug 20
Equillium Announces Proposed Public Offering of Common Stock
4:50pm
8-K
EX-99.2
pk8ko8cfvxv
14 Aug 20
Equillium Announces Proposed Public Offering of Common Stock
4:50pm
424B5
8dbhq9
14 Aug 20
Prospectus supplement for primary offering
4:45pm
424B5
ts2iwc
13 Aug 20
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
uewxnpnm11kt
12 Aug 20
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
8:40am
8-K
EX-99.1
nx8w0om 29j992ols
10 Aug 20
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
5:21pm
8-K
kpru ghlkhn6ir0
10 Aug 20
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
5:21pm
424B5
7vqbc3gldik27e
14 Jul 20
Prospectus supplement for primary offering
6:05am
8-K
EX-99.1
qdtbo
13 Jul 20
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon
6:05am
8-K
EX-99.1
2mc4a
13 May 20
Equillium Reports First Quarter 2020 Financial Results
4:10pm
424B3
cszn nmahak
7 Apr 20
Prospectus supplement
4:57pm
8-K
EX-10.1
7agwuom6
30 Mar 20
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
lihmbw1
26 Mar 20
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
1rpcqu ksb
12 Dec 19
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to
7:05am